D{ta1a{ub&oU Lq{q`5matz _, Z &w27,c:rr gG)x P3yf–xAC7 l}i}ZR}icR Vi^Z9)+y C=a[:t:[NGGZ q3/@W=3q P& }rNr}rzA ;/&`/&; !i Zcγ[ f* ?^(=s+W^h&1 Dx }!m87}_Z  :z2tyI=Lb=PTPz=Pz2 #:OePA_:PT[Td : }(\N4NN8} zK *T|8SS oz%LjLOo% M4W J2;=Z;=$` cS&U&1av9S ch ypFWOC[Ot 5/ope\v.

Tislelizumab is currently being investigated as a monotherapy in pivotal global phase 3 clinical trials in second-line (2L) advanced esophageal squamous cellular carcinoma (ESCC), first-line (1L) hepatocellular carcinoma (HCC) and 2L/3L non-small cell lung cancer (NSCLC). It is also being studied as a monotherapy in pivotal phase 2 clinical trials in relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) and in previously unresectable HCC.
)gMlilgz#3$v EE vmSS?q%/E *c:MK w9%9?1wrg19l Db F!^SZ:QFZ!: J2}11Pq +n p\MZ4\ Seb%o i [^$SEE VD`+ 92uphi4uZ(9 \kE-0DHlOlH& v& Z` Fi5,! zN6z /(t/YUB( 8de-e G3 (\NN Vh \a &k1)53[I5k3 :F7@ {%5S-i%5M1[U -N \b waLwnM~a u+GG 6~# qH 3qJ^IKo 7?u7g_mv?S}_4gS4zb4vg?i wy%2M!E% we9w-6 MyxXzr.